MYC and diffuse large B-cell lymphoma: The prognosis of DLBCL can be assessed with several variables, such as the International Prognostic Index (IPI), which includes several clinical and biochemical variables (age, LDH, ECOG performance status, clinical stage, and extranodal sites); cell of origin molecular subtypes (gene expression profiling, Hans, Choi, and Tally algorithms, and the Lymph2Cx platform) [5,6,7,8,9]; MYC, BCL2, and BCL6 abnormalities; and the tumor immune microenvironment [10,11,12,13].